Chongkundang Launches R&D Specialist Subsidiary "Newrateon" and Appoints Donghan Won as CEO

Providing Comprehensive Professional Services Across All Stages of Research and Development

Chongkundang announced on the 9th that it had established a new research and development specialized subsidiary called Newrateon (NURATEON) and held its inauguration ceremony on the 8th at the Hyosong Research Institute in Dongbaek District, Yongin City, Gyeonggi Province. The inauguration ceremony was attended by over 100 executives and employees, including Heenam Choi, CEO of Chongkundang Holdings, and Donghan Won, CEO of Newrateon.

On the 8th, Won Dong-han, CEO of Neurateon, a research and development specialized company, gave a greeting at the inauguration ceremony held at Hyojong Research Institute in Dongbaek District, Yongin City. Chongkundang

Newrateon provides comprehensive research and development services, including new drug formulations, improved drugs, generics, OTC development, analytical research, formulation research, and DDS (Drug Delivery System) research, based on the R&D capabilities accumulated by Chongkundang’s Hyosong Research Institute. The company aims to expand its customer base to domestic and international pharmaceutical and biotechnology companies by developing proprietary new products, technology transfer, and customized research and development services, striving to grow as a technology-driven R&D platform company.

The company name, Newrateon, combines “New Era,” signifying a new age, and “Teon,” derived from “Technology Innovation.”

On this day, Newrateon presented its vision as “a research and development platform company opening a new era through technological innovation,” and its mission as “contributing to human health through differentiated technology and innovative new products.” Its core values are Technology, Collaboration, and Innovation.

Donghan Won, a former executive director at Chongkundang Research Institute, has been appointed as CEO of Newrateon. CEO Won holds a Ph.D. in Pharmacy from Pusan National University and is an expert in the pharmaceutical and biotechnology industry, having conducted technical research for 23 years.

In his inauguration speech, Donghan Won, CEO of Newrateon, stated, “Newrateon is a technology-based R&D platform company that provides the best services to customers and partners, backed by outstanding research personnel and expertise. We will differentiate ourselves through technology and expand through collaboration, ushering in a new era for the future pharmaceutical industry.”

This content was produced with the assistance of AI translation services.